Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by juniper88on Oct 07, 2021 2:41pm
153 Views
Post# 33983328

RE:Expectations for Next Week

RE:Expectations for Next WeekMy wife currently is on Niraparib, a parp inhibitor for recurrent ovarian cancer maintenance.  It doesn't usually kill the cancer be can delay it from returning.  Anyway, the cost in canadian dollars is $8047 for a box, which is 28 days worth of capsules.  Btw, the medicine doesn't even do that much for someone like my wife who is not BRCA or HRD positve.  Still, in USD about $80k/year.

SPCEO1 wrote:

Paul also mentioned 10,000 potential patients in the recent presentation. So, if they were able to get 10,000 patients and the drug had a price tag of $10,000, then that is a $100 million in annual revenue. If a price tag of $20,000, $200 million and so on. Does anyone have a good idea of what price range a drug like TH-1902 might be found?  


<< Previous
Bullboard Posts
Next >>